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Abstract  15 
Norovirus full genome sequencing is challenging due to sequence heterogeneity between 16 
genomes. Previous methods have relied on PCR amplification, which is problematic due to 17 
primer design, and RNASeq which non-specifically sequences all RNA in a stool specimen, 18 
including host and bacterial RNA. 19 
Target enrichment uses a panel of custom-designed 120-mer RNA baits which are 20 
complementary to all publicly available norovirus sequences, with multiple baits targeting 21 
each position of the genome, thus overcoming the challenge of primer design. Norovirus 22 
genomes are enriched from stool RNA extracts to minimise sequencing non-target RNA. 23 
SureSelect target enrichment and Illumina sequencing was used to sequence full genomes 24 
from 507 norovirus positive stool samples with RT-qPCR Ct values 10–43. Sequencing on an 25 
Illumina MiSeq in batches of 48 generated on average 81% on-target-reads per sample and 26 
100% genome coverage with >12,000-fold read depth. Samples included genotypes GI.1, 27 
GI.2, GI.3, GI.6, GI.7, GII.1, GII.2, GII.3, GII.4, GII.5, GII.6, GII.7, GII.13, GII.14 and GII.17. Once 28 
outliers are accounted for, we generate over 80% genome coverage for all positive samples, 29 
regardless of Ct value.  30 
164 samples were tested in parallel with conventional PCR genotyping of the capsid shell 31 
domain. 164/164 samples were successfully sequenced, compared to 158/164 that were 32 
amplified by PCR. Four of the samples that failed capsid PCR had low titres, suggesting 33 
target enrichment is more sensitive than gel-based PCR. Two samples failed PCR due to 34 
primer mismatches; target enrichment uses multiple baits targeting each position, thus 35 
accommodating sequence heterogeneity between norovirus genomes. 36 
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Introduction 37 
Norovirus is a leading cause of outbreaks of acute gastroenteritis (1, 2) with an estimated 38 
prevalence of 20% in cases of acute gastroenteritis in developed countries (3) and a high 39 
financial burden in healthcare settings associated with ward and hospital closures (4).  In 40 
countries where rotavirus vaccine has been introduced, norovirus is now the leading cause 41 
of medically-attended gastroenteritis in children (5, 6). 42 
Norovirus has a 7.5kb single stranded RNA genome, organised into 3 open reading frames; 43 
ORF1, ORF2 and ORF3. ORF1 encodes a non-structural polyprotein which is cleaved post-44 
translationally and includes the RNA-dependent RNA polymerase. ORF2 encodes the major 45 
structural capsid protein, which is divided into shell (S) and protruding (P) domains. The P 46 
domain has two subdomains, P1 and P2. P2 is the most exposed antigenic site and contains 47 
immunogenic epitopes; consequently it has the greatest sequence variation. ORF3 codes for 48 
a minor capsid protein.  49 
 50 
Comparison of viral genetic sequences allows linking of previously unrecognised 51 
transmission events or exclusion of cases from an outbreak. Traditionally,  52 
norovirus genotyping has involved polymerase chain reaction (PCR) amplification and 53 
capillary sequencing of partial regions of the polymerase and capsid sequences, followed by 54 
additional sequencing of the P2 region for outbreak investigations. This is a labour intensive 55 
process requiring several rounds of PCR and sequencing, each requiring genogroup or 56 
genotype specific primers and only yields partial genome sequences at the end.  Moreover, 57 
whilst the P2 domain can identify linked outbreak events with 64–73% specificity (assuming 58 
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bootstrap support >70 or <70, respectively), the full capsid sequence can identify linked 59 
outbreak events with 100% specificity (7) and thus is more informative.  60 
Whole genome sequencing simplifies investigation of norovirus molecular epidemiology by 61 
generating all the regions of interest in one step, thus allowing identification of the 62 
genotype, variant type and full capsid sequence; negating the need for sequential PCR and 63 
sequencing reactions. However, unlike bacteria, which can be isolated in pure culture, 64 
norovirus culture is difficult (8).  Moreover, as norovirus replicates within the host cell, viral 65 
nucleic extracts are contaminated by host DNA, and if obtained from clinical specimens, by 66 
DNA and RNA from enteric bacteria.  67 
To date norovirus sequencing from clinical material has been achieved by two methods: 68 
sequencing of overlapping PCR fragments (9-12) and direct sequencing of total RNA (13-16). 69 
The former generates pure viral template, which improves the quality of sequence, but 70 
requires multiple PCR amplifications.  The latter necessitates great depth of sequencing to 71 
generate the target norovirus genome. Here we describe the application of a third method, 72 
SureSelect target enrichment (Agilent), which has been successfully used to generate full 73 
pathogen genomes for hard to culture bacteria as well as DNA and RNA viruses directly from 74 
clinical samples (17-19).  Norovirus genomes are enriched directly from stool RNA extracts 75 
using a panel of custom-designed 120-mer RNA baits which are complementary to all 76 
publicly available norovirus sequences, with multiple baits targeting each position of the 77 
genome. This approach overcomes the problems of primer design in PCR and of non-target 78 
sequencing in RNASeq.   79 
Materials and Methods 80 
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Samples 81 
507 norovirus positive stool samples from 382 patients in four UK healthcare centres were 82 
processed for whole genome sequencing. Samples included genotypes GI.1, GI.2, GI.3, GI.6, 83 
GI.7, GII.1, GII.2, GII.3, GII.4, GII.5, GII.6, GII.7, GII.13, GII.14 and GII.17, as detailed in Table 84 
1. The presence of norovirus was verified in all samples using a multiplex norovirus GI and 85 
GII-specific one-step reverse-transcription real-time PCR (RT-qPCR); the primer and probe 86 
sequences and cycling conditions have been previously described (manuscript submitted to 87 
J Clin Virol). For 78/507 samples provided by one of the centres, the presence of norovirus 88 
RNA was not verified in the re-extracted residual specimen; for these samples the RT-qPCR 89 
Ct value corresponds to the original extract used as part of diagnostic service. The RT-qPCR 90 
cycle threshold (Ct) value is used in this study as a semi-quantitative indicator of viral titre. 91 
All specimens were residual diagnostic specimens obtained from patients with confirmed 92 
norovirus infections. Specimens were submitted to the UCL Infection DNA Bank for use in 93 
this study. All samples were supplied to the study in an anonymised form; the use of these 94 
specimens for research was approved by the NRES Committee London – Fulham (REC 95 
reference:  12/LO/1089). All stool samples were stored at −80°C in between diagnostic 96 
testing and RNA extraction for full genome sequencing.   97 
164 stool samples were genotyped using capsid PCR and Sanger sequencing in parallel to 98 
SureSelect target enrichment whole genome sequencing. PCR primer sequences and cycling 99 
conditions for genotyping have been described previously (manuscript submitted to J Clin 100 
Virol). Briefly, GI or GII-specific primers were used to amplify a 597 or 468 nt region of the 101 
norovirus capsid shell domain, respectively; amplicons were capillary sequenced in the 102 
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forward and reverse direction. Generated sequences were submitted to the Norovirus 103 
genotyping tool to identify the capsid genotype (20).   104 
RNA extraction 105 
RNA was purified from 200 µl of a clarified 10% w/v stool suspension using the Qiagen EZ1 106 
virus mini kit or Qiasymphony DSP Virus/Pathogen kit with a 90 µl elution volume. All 107 
purified RNA was stored at −80°C prior to cDNA synthesis. 108 
cDNA synthesis 109 
RNA extracts were concentrated to 11 µl using a vacuum centrifuge at 65oC prior to first 110 
strand cDNA synthesis. First strand cDNA was synthesised using random primers and 111 
SuperScript III (SS III, Life Technologies) as per manufacturer’s instructions. Briefly, 1 µl of 112 
10mM (each) dNTP mix and 1 µl of 3 µg/ml random primers were incubated with 11 µl RNA 113 
for five minutes at 65 °C to anneal primers to RNA template, followed by incubation on ice 114 
for 1 minute. RNA–primer templates were mixed with 4 µl 5x first strand buffer, 1 µl 0.1M 115 
DTT, 1 µl RNase OUT and 1 µl SS III at 25 °C for 5 minutes followed by cDNA synthesis at 50 116 
°C for 1 hour and enzyme inactivation at 70 °C for 15 minutes. Second strand cDNA was 117 
synthesised using Second Strand cDNA Synthesis kit (NEB) as per manufacturer’s instruction. 118 
Briefly, 20 µl first strand cDNA was incubated with 48 µl water, 8 µl 10x 2nd strand buffer 119 
and 4 µl 2nd strand enzyme mix at 16 °C for 2.5 hours. Double stranded cDNA was purified 120 
and concentrated with Genomic DNA Clean and Concentrator (Zymo Research), as per 121 
manufacturer’s instructions, with a 30 µl elution volume and quantified with Qubit dsDNA 122 
high sensitivity (HS) kit (Invitrogen). 123 
SureSelect Target Enrichment: RNA baits design 124 
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Overlapping 120-mer RNA baits complementary to and spanning the length of 622 norovirus 125 
partial or complete genomes from Genbank were designed using an in-house PERL script. 126 
Briefly, a 120 nucleotide sliding window is scanned along each reference genome at 127 
intervals of 10 nucleotides. If the 120-mer is sufficiently different to other 120-mer 128 
sequences in the baitset (as assessed by BLAT (21)), it is retained in the baitset; otherwise 129 
that 120-mer is discarded. In this way, the baitset spans the diversity in all of the included 130 
reference genomes. The baitset is available upon request. The reference genomes included 131 
samples from polymerase genotypes GI.P1, GI.P2, GI.P3, GI.P4, GI.P6, GI.P8, GI.Pb, GI.Pc, 132 
GI.Pd, GI.Pf, GII.P1, GII.P2, GII.P3, GII.P4, GII.P5, GII.P6, GII.P7, GII.P8, GII.P11, GII.P12, 133 
GII.P15, GII.P16, GII.P17, GII.P18, GII.P21, GII.P22, GII.Pc, GII.Pe, GII.Pg, GII.Pp, GIII, GIV, GV 134 
and GVI and capsid genotypes GI.1, GI.2, GI.3, GI.4, GI.5, GI.6, GI.8, GII.2, GII.3, GII.4, GII.5, 135 
GII.6, GII.7, GII.8, GII.10, GII.11, GII.12, GII.13, GII.14, GII.15, GII.16, GII.17, GII.18, GII.21, 136 
GII.22, GIII, GIV, GV and GVI. The GII.4 reference genomes included samples from all major 137 
GII.4 strains: CHDC1970s, Bristol 1993, Camberwell 1994, US95/96, Farmington Hills 2002, 138 
Lanzhou 2002, Asia 2003, Hunter 2004, Yerseke 2006a, Den Haag 2006b, Osaka 2007, 139 
Apeldoorn 2007, New Orleans 2009 and Sydney 2012. The custom designed norovirus bait 140 
library was uploaded to Agilent SureDesign and synthesised by Agilent Biotechnologies.     141 
 142 
SureSelect Target Enrichment: Library preparation, hybridisation and enrichment  143 
Norovirus cDNA samples were quantified and carrier G147 Human Genomic DNA: male 144 
(Promega) was added if necessary to obtain a total of 200ng.  145 
All DNA samples were mechanically sheared for 150 seconds using a Covaris E210 focused-146 
ultrasonicator (duty cycle 5%, PIP 175 and 200 cycles per burst) to yield a fragment size of 147 
approximately 270 bp. End-repair, non-templated addition of 3’ –A adapter ligation, 148 
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hybridisation, enrichment PCR and all post-reaction clean-up steps were performed 149 
according to the SureSelect Illumina Paired-End Sequencing Library XT protocol. All 150 
recommended quality steps were performed between steps. 151 
Negative controls 152 
All RNA extraction batches included a negative extract control, consisting of sterile Qiagen 153 
Buffer ASL extracted with the Qiagen EZ1 virus mini kit alongside stool samples. All negative 154 
extracts were tested by norovirus-specific real-time RT-PCR to verify the absence of 155 
contaminating RNA. 156 
To determine the level of contaminating norovirus RNA in the sequencing pipeline, two 157 
negative extracts were processed for sequencing.  158 
Illumina sequencing 159 
Samples were multiplexed with 48 samples per run. Paired end sequencing was done on an 160 
Illumina MiSeq sequencing platform with the 500 cycle v2 Reagent Kit.  Base calling and 161 
sample demultiplexing were generated as standard on the MiSeq producing paired FASTQ 162 
files for each sample.  163 
Sequence assembly 164 
All assemblies were done in CLC genomics workbench v8, as summarised in Figure 1. All 165 
reads were quality trimmed and adapter sequences removed. Trimmed reads were mapped 166 
to a curated reference list consisting of all norovirus complete genome and complete gene 167 
sequences in Genbank as of 14/07/2015 (n = 688). All paired reads mapping to the reference 168 
list (filtered reads) were taken forward to de novo assembly using workbench default 169 
parameters and a minimum contig length of 200 nucleotides. Contigs generated from the de 170 
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novo assembly were aligned to a single Genbank reference sequence of the relevant 171 
genotype to check the orientation of the contig and, where multiple contig sequences were 172 
generated, the position of each contig relevant to the reference. Multiple contig sequences 173 
were joined based on overlapping nucleotide sequences or with a manually inserted gap. All 174 
trimmed reads (pre-filtering) were mapped to the full length contig sequence generated 175 
from the de novo assembly to generate a final consensus sequence. Areas of low coverage 176 
(<10) were assigned the ambiguity symbol N. 177 
Simulated mixed infection 178 
To assess whether a reliable consensus sequence can be generated from a mixed infection, 179 
the reads generated from two single infections (one GII.3 and one GII.4) were merged into a 180 
single assembly pipeline. The consensus sequences generated from the single infection 181 
(original) and the mixed (simulated) infection were aligned to identify the number of 182 
differences between the two consensus sequences.  183 
Statistical analysis 184 
All statistical analysis was performed in SPSS v23 using two-tailed tests at the 5% 185 
significance level. 186 
The difference in % on-target-reads (% OTR), read depth and % genome coverage between 187 
norovirus genotypes and in PCR Ct value between Pass/Sub-optimal/Failed samples  was 188 
tested by Kruskal-Wallis ANOVA, with pairwise multiple comparison of significant results 189 
and P values adjusted for multiple comparisons.  190 
The relationship between PCR Ct value and % OTR, read depth and % genome coverage was 191 
assessed by Spearman’s correlation.  192 
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A simple linear regression model (independent variable, PCR Ct value; dependant variable, 193 
logit transformed %genome coverage) was fitted to generate prediction intervals for % 194 
genome coverage from the PCR Ct value. % genome coverage was transformed using the 195 
formula 𝑡𝑟_𝑔𝑒𝑛𝑜𝑚𝑒 =
%𝑔𝑒𝑛𝑜𝑚𝑒 𝑐𝑜𝑣𝑒𝑟𝑎𝑔𝑒 ×(𝑁−1)+0.5
𝑁
 to ensure there are no proportions of 0 196 
or 1 and then transformed again using the logit function 197 
(𝑙𝑜𝑔𝑖𝑡 𝑡𝑟𝑎𝑛𝑠𝑓𝑜𝑟𝑚𝑒𝑑 %𝑔𝑒𝑛𝑜𝑚𝑒 𝑐𝑜𝑣𝑒𝑟𝑎𝑔𝑒 = log (
𝑡𝑟_𝑔𝑒𝑛𝑜𝑚𝑒
1−𝑡𝑟_𝑔𝑒𝑛𝑜𝑚𝑒
) where log is the natural 198 
logarithm with base ℯ. Outliers (highlighted in Figure A3) were excluded from regression 199 
analysis. 200 
Results 201 
Overall sequencing outcomes  202 
Since the aim was to generate full genome sequences, we defined the cut-off for sequencing 203 
success as >90% coverage of the full norovirus genome with >100-fold mean read depth to 204 
ensure a robust consensus sequence. Samples that met only one of these criterions were 205 
categorised as “sub-optimal”, and those which did not meet either criteria were considered 206 
a “fail”.  207 
Of 507 samples across all sampled genotypes, 453 (89%) passed; i.e. had >90% genome 208 
coverage and >100-fold read depth (Table 1, Figure 2, Figure A1). However in total, 93% of 209 
samples had a genome coverage of >90% at any depth. A median of 81.22% of the total 210 
sequencing reads generated for each sample mapped to the norovirus genome, referred to 211 
as the % on-target-reads (% OTR). On average, 100% of the full genome was covered (% 212 
genome coverage) with median read depth of 12,227-fold (Table 1).   213 
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There was no significant difference in % OTR (P = 0.127), mean read depth (P = 0.398) or % 214 
genome coverage (P = 0.203) between norovirus genotypes (Figure 3 (a–c)). 215 
A significant correlation was found between % OTR and read depth (R = 0.757, P <0.001, 216 
Figure A2) and between PCR Ct value and (i) % OTR (R = −0.536, P <0.001), (ii) read depth (R 217 
= −0.468, P <0.001) and (iii) % genome coverage (R = −0.223, P <0.001) (Figure 3 (d–f)). It 218 
follows that there is a significant difference in PCR Ct value between samples that passed 219 
compared to those that were sub-optimal (P <0.001) or failed (P <0.001) with median Ct 220 
values of 22, 32 and 32, respectively (Figure 4). There is an inverse relationship between Ct 221 
value and viral load (22); thus samples with a smaller Ct value (higher viral titre) resulted in 222 
higher %OTR, read depth and genome coverage.  223 
Predicted genome coverage 224 
The estimated linear regression model is 𝑦 = 7.432 − 0.059𝑥 where the dependent 225 
variable y is the logit of transformed genome coverage proportion and the independent 226 
variable x is the PCR Ct value (n = 477, R2 = 0.058, P <0.001).  227 
 228 
Prediction intervals generated using the linear regression model predict that stool samples 229 
with a norovirus RT-qPCR Ct value <40 will generate 92–100% of the full genome sequence, 230 
with 95% certainty (Figure 5).  231 
Failed samples 232 
The outliers in Figure 3(f) are dominated by samples from two sequencing runs (#30 and 31; 233 
Figure A3), which were known to have had processing problems during cDNA preparation. 234 
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Six of the 16 samples with Ct <30 and genome coverage <80% had sufficient residual 235 
specimen to be repeated; all of these passed on repeat. 236 
Three samples (highlighted in Figure A3, detailed in Table A1) generated unexpectedly low % 237 
genome coverage (49–73%) given the RT-qPCR Ct values (22–29) but were not part of 238 
sequencing runs 30 or 31. Sequences from all three samples were fragmented throughout 239 
ORF 1, with ORF3 and ORF2 downstream from the capsid protruding domains, P1 and P2 240 
absent (Figure A4). In all three cases, the % OTR (0.01, 2.53 and 6.76%) and average read 241 
depth (1-, 120- and 137-fold) was low for ORF 1 despite apparently good Ct values. Coverage 242 
of ORF 1 and the 5’ end of ORF 2 was sufficient to confirm two samples as GII.4 and one as 243 
GII.5 using the norovirus genotyping tool; we have shown good sequencing outcomes for 244 
both genotypes in other samples (Table 1). It is not possible to exclude the possibility of a 245 
novel recombinant strain, with recombination at the P1/P2 junction in ORF2, and 246 
subsequent failure due to missing complementary baits in the enrichment; however if this 247 
were the case we would expect to see good coverage of the enriched region, in this case 248 
ORF 1, which we do not. Moreover all three samples had been re-extracted at referring 249 
centres and the Ct value supplied was obtained from PCRs carried out on the original 250 
diagnostic extracts. This, combined with the low coverage of ORF 1, suggests that extraction 251 
failure at the local hospital may explain the unexpected sequencing failure. It has not been 252 
possible to test either possibility, since none of the original sample remains.  253 
Low titre samples 254 
Seven samples generated full genome sequences despite low viral titres (PCR Ct ≥36). To 255 
determine whether these samples had misleadingly late Ct values due to a mismatch in the 256 
RT-qPCR primer target region, the seven genome sequences were aligned to the RT-qPCR 257 
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primer and probe sequences used to generate the Ct value. There were no mismatches in 258 
the primer or probe sites (Figure A5), suggesting they are genuinely low titre samples and 259 
confirming the sensitivity of the method for low titre samples. 260 
Comparison to capsid genotyping 261 
96% (158/164) and 100% (164/164) of samples processed in parallel were successfully 262 
genotyped by PCR with Sanger sequencing and by our method, respectively (Table A2). For 263 
the 158 samples typed by both methods, there was 100% agreement in the respective 264 
genotypes. Of the 6 samples that failed capsid typing by PCR, four were GII.4, one GII.7 and 265 
one GI.3 (Table A3).  266 
Two of the failed samples, with Ct values 20 and 27, had mismatches at the genotyping 267 
primer sites (Figure A6) which accounts for genotyping failure in these instances.  268 
The remaining four of the six samples that failed genotyping had Ct values >30 (range 31–269 
37), which suggests the genotyping PCR is less sensitive than sequencing by target 270 
enrichment. 271 
Contamination 272 
Two “negative extract” samples, consisting of Buffer ASL that was treated in the same way 273 
as, and alongside, stool samples, were negative for norovirus RNA by RT–qPCR. Nonetheless 274 
target enrichment and sequencing generated 16–36% OTR with 3–81-fold read depth. The 275 
genome coverage for each sample was only 9 and 12%, with reads fragmented across the 276 
genome (Figure A7 and Figure A8). The mapped regions do not correspond to PCR amplicon 277 
sites. 278 
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Mixed infections 279 
Three (3/507) samples were identified as having sequences from more than one genotype 280 
during the assembly pipeline (Table A4). For two of the samples, the mixed infections were 281 
evident during the “mapping to reference list” step of the de novo pipeline (Figure 1), in 282 
which reads mapped to reference sequences corresponding to multiple norovirus 283 
genotypes, as per Table A4. For the third sample, mixed infection was evident during the 284 
“align contigs to single reference of appropriate genotype” step, in which a full length contig 285 
mapped to the reference sequence at ORF1 but not at ORF 2 and ORF 3.  286 
Comparison of the consensus sequences generated from a single infection and from a 287 
simulated mixed infection showed 178–332 single nucleotide polymorphisms (SNPs) and 288 
95.53–97.61% sequence identity between the consensus sequences from the single and 289 
mixed datasets (Table A5).  290 
Turn-around times and costs 291 
The turn-around times associated with full genome sequencing by SureSelect target 292 
enrichment is 6 days; three days longer than genotyping (RNA-dependent RNA polymerase 293 
and capsid regions) by PCR and Sanger sequencing with an extra associated cost of £54 294 
when reagents are purchased in bulk (Table 2). 295 
Discussion 296 
Target enrichment is a highly effective method for sequencing norovirus full genomes across 297 
genotypes with a high read depth averaging over 12,000-fold and complete or almost 298 
complete genomes in 89% of samples. We report median genome coverage of 100% across 299 
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all sequenced samples and, once outliers are accounted for, over 80% genome coverage 300 
regardless of the viral titre.  301 
However, despite good molecular practice, low level contamination does occur. Since 302 
negative extracts were RT-qPCR negative but target enrichment yielded reads that map to 303 
the norovirus genome, we suspect the source of contamination is the automated equipment 304 
used for target enrichment and sequencing library preparation. In the context of norovirus-305 
positive specimens, the contamination is low; reads are fragmented and only map to 9-12% 306 
of the genome with <100-fold read depth, which is significantly below the observed median 307 
% genome coverage and read-depth seen for norovirus-positive samples (100% and 308 
>12,000-fold, respectively) and below the 95% prediction intervals for % genome coverage 309 
(92–100% for a sample with Ct <40). These findings support our acceptance criteria for 310 
downstream analysis, which is >100-fold read depth and >90% genome coverage. Where a 311 
complete genome sequence is not critical for downstream analysis, based on the 95% 312 
prediction intervals, >60% genome coverage would be acceptable if read depth is >100-fold. 313 
However due to the potential for low level contamination, specimens for which norovirus 314 
RNA is not detectable by real-time PCR should not be sequenced.  315 
Previous reports have described whole norovirus genome sequencing with overlapping PCR 316 
amplicons or using RNASeq, the findings of which are summarised in Table A6. PCR- based 317 
methods yield high read depth; however, due to sequence heterogeneity between 318 
genotypes, primers generally need to be genotype specific (9). Broad-range primers have 319 
been reported by Cotton et al. (10) nonetheless this approach retains a limited success rate; 320 
full genome sequences were amplified from a comparable proportion of samples of GII.13 321 
(83% versus 100% in this study), GII.6 (88% vs. 95%) and GII.4 (92% vs. 89% or 93% 322 
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irrespective of read depth). However PCR fared worse, recovering fewer full genomes from 323 
GI (20% vs. 100% in this study), GII.2 (40% vs. 88%), GII.3 (77% vs. 87% or 90% irrespective of 324 
read depth) and GII.7 (0% vs. 90%). Norovirus whole genome sequencing from a single 7.5 325 
kb amplicon has also been described and used to generate 25 full genome sequences (23) 326 
however the authors do not report the success rate using this approach; it is generally very 327 
difficult to amplify fragments of such a size. Conversely here we report complete or nearly-328 
complete genome sequences in 93% of processed samples. In target enrichment, baits are 329 
designed using all publically available norovirus sequences, across all GI and GII genotypes; 330 
unlike PCR which uses a single primer at each target site,  multiple baits are designed to 331 
cover each position in the genome thus accounting for sequence variation between 332 
norovirus genomes. This allows un-biased sequencing across known genotypes in a single 333 
reaction. A disadvantage of the method is that it may fail to generate sequences for a newly 334 
emerging genotype where the existing baits are a poor match.   335 
Whole transcriptome sequencing, or RNASeq, involves sequencing the total RNA or mRNA 336 
content of a stool specimen. The advantage of RNASeq is that there is no requirement for 337 
PCR primers therefore it is completely unbiased. Although all whole genomes by RNASeq 338 
reported to date are predominantly GII.4, it is theoretically possible to sequence all 339 
genotypes with equal success as evidenced by Bavelaar et al who successfully sequenced 340 
five non-GII.4 genomes (16). The data generated by RNASeq is sufficient to generate almost 341 
complete norovirus genome sequences; 40–100% of reported samples achieved >90% 342 
genome coverage (13-16) (summarised in Table A6). However the median % OTR across all 343 
reported samples is only 2–3% using a MiSeq or HiSeq (13, 15) and 28% using an Ion Torrent 344 
PGM (16), compared to 81% OTR by SureSelect target enrichment. The high proportion of 345 
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non-target data using RNASeq makes the technique uneconomical and, critically, results in 346 
low read depth; on average only 9–259-fold using a MiSeq or HiSeq (13-15) and 1,309 using 347 
an Ion Torrent PGM (16). Conversely, the median read depth using target enrichment is over 348 
12,000-fold which allows large sample batches to be sequenced on a single MiSeq run and 349 
downstream analysis of minority variants.  350 
Our de novo assembly pipeline identified mixed genotype infections in three samples. 351 
However with as many as 332 SNPs between the consensus sequences generated from a 352 
single and simulated mixed infection, we suggest that a reliable consensus sequence cannot 353 
be generated using this assembly pipeline. This is due to mis-mapping of reads in relatively 354 
conserved regions, as evidenced by the majority of SNPs being found in ORF1 (163/178 and 355 
284/332 in the GII.3 and GII.4 consensus sequences respectively). Thus whilst this pipeline 356 
can identify infections with a mixture of genotypes, an alternative approach is required for 357 
assembly and generating the consensus sequence, possibly involving the use of minority 358 
variants and haplotype reconstruction.  359 
We have shown target enrichment to be superior to PCR capsid amplification for 360 
genotyping; all samples (164/164) that were processed in parallel successfully generated 361 
genome sequences by target enrichment, whereas 96% (158/164) were successfully 362 
amplified by capsid typing PCR. Four of the six samples that failed capsid genotyping but 363 
were sequenced by target enrichment had low norovirus titres (based on PCR Ct values), 364 
which suggests target enrichment is more sensitive than the conventional genotyping 365 
methods. The remaining two failed samples had primer mismatches that account for 366 
amplification failure. Target enrichment overcomes the limitations of primer design by 367 
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allowing multiple baits with different sequences to target each region of the genome, thus 368 
accounting for sequence heterogeneity in a way that PCR primers cannot. 369 
Unlike classical genotyping, which requires sequential PCR and sequencing reactions yielding 370 
only fragments of the genome in return, full genome sequences can, in a single reaction, 371 
provide us with the RNA polymerase and capsid sequences, which are important for 372 
genotyping,  and in addition can identify recombination and reveal minority variants in the 373 
intra-host viral population. The cost of targeted enrichment whole genome sequencing is 374 
around £50 more expensive than PCR genotyping of the capsid and polymerase genes. 375 
However, whole genome sequencing using overlapping amplicons is comparable in cost to 376 
enrichment methods. Turnaround time for the target enrichment is 6 days compared to 377 
three days for capsid and polymerase genotyping. The semi-automated target enrichment 378 
hands-on-time is 4 hours more than conventional genotyping and comparable to RNASeq. A 379 
current drawback is the need for batch processing of samples to achieve the costs savings.  380 
This is feasible for a regional sequencing service or a named study, but might be difficult for 381 
a diagnostic laboratory.  Further developments to shorten hybridization and sequencing 382 
times and to enable random access processing would address these drawbacks. 383 
The advancement of sequencing techniques, from PCR with capillary sequencing to target 384 
enrichment with deep sequencing, facilitates the use of norovirus full genomes in clinical 385 
practice. In conjunction with growing expertise, lower costs and faster turn-around times, 386 
full genomes can be sequenced for under £100 in less than a week; this makes full genome 387 
sequencing a reality not just in academic settings but for informing public health practice in 388 
real time. 389 
 390 
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Table 1. Metrics of norovirus whole genome sequencing for all samples (TOTAL) and for each genotype.  484 
Pass, >90% genome coverage and >100-fold read depth; Sub-optimal, >90% genome coverage or >100-fold read depth; Fail, <90% genome 485 
coverage and <100-fold read depth; n/a, range not applicable due to single sample; % OTR, percent on target reads; Ct, real-time PCR cycle 486 
threshold; GI.ut, genogroup I untypable; GII.ut, genogroup II untypable; NegEx, negative control487 
 
Number of 
samples 
sequenced 
Number 
samples 
Pass (%) 
Number 
samples Sub-
optimal (%) 
Number 
samples 
Fail (%) 
Median % OTR 
(min–max) 
Median read depth 
(min–max) 
Median % genome 
coverage (min–
max) 
Median Ct 
values (min–
max) 
GI.1 2 2 (100%) 0 (0%) 0 (0%) 63.05 (43.85-82.25) 11,194 (7,239–15,149) 100 (100–100) 31 (30–32) 
GI.2 4 4 (100%) 0 (0%) 0 (0%) 77.60 (2.17-94.70) 11,464 (379–21,843) 100 (99–100) 29 (24–33) 
GI.3 15 15 (100%) 0 (0%) 0 (0%) 74.13 (1.08-93.25) 13,157 (246–27,569) 100 (90–100) 27 (17–35) 
GI.6 1 1 (100%) 0 (0%) 0 (0%) 86.56 (n/a) 8,642 (n/a) 100 (n/a) 29 (n/a) 
GI.7 1 1 (100%) 0 (0%) 0 (0%) 83.88 (n/a) 18,414 (n/a) 100 (n/a) 21 (n/a) 
GI.ut 2 1 (50%) 0 (0%) 1 (50%) 40.34 (9.50-71.18) 7,000 (42–13,957) 91 (83–100) 29 (23–35) 
GII.1 3 3 (100%) 0 (0%) 0 (0%) 95.61 (20.06-97.04) 11,990 (4,365–16,506) 100 (99–100) 15 (14–31) 
GII.13 1 1 (100%) 0 (0%) 0 (0%) 77.44 (n/a) 10,043 (n/a) 100 (n/a) 21 (n/a) 
GII.14 6 6 (100%) 0 (0%) 0 (0%) 53.31 (4.20-81.60) 10,238 (1,081–15,215) 100 (100–100) 27 (21–32) 
GII.17 2 2 (100%) 0 (0%) 0 (0%) 63.30 (40.27-86.33) 13,204 (8,598–17,811) 100 (100–100) 24 (21–27) 
GII.2 24 21 (88%) 0 (0%) 3 (12.5%) 57.60 (0.60-99.47) 4,717 (7–23,889) 100 (64–100) 24 (18–32) 
GII.3 105 91 (87%) 3 (2.9%) 11 (10.5%) 85.00 (0.02-99.36) 16,034 (7–38,843) 100 (3–100) 21 (10–38) 
GII.4 281 250 (89%) 12 (4.3%) 19 (6.8%) 83.75 (0.02-99.63) 12,465 (1–46,996) 100 (5–100) 22 (12–43) 
GII.5 6 5 (83%) 0 (0%) 1 (16.7%) 70.21 (0.04-97.13) 16,468 (1–29,488) 100 (49–100) 19 (16–23) 
GII.6 40 38 (95%) 0 (0%) 2 (5%) 70.32 (0.45-98.23) 9,356 (3–31,643) 100 (22–100) 21 (13–33) 
GII.7 10 9 (90%) 0 (0%) 1 (10%) 53.14 (2.72-83.88) 12,779 (2,106–26,914) 100 (96–100) 25 (22–30) 
GII.ut 4 3 (75%) 1 (25%) 0 (0%) 49.02 (0.59-92.61) 11,356 (98–23,588) 100 (94–100) 25 (19–35) 
NegEx 2 0 (0%) 0 (0%) 2 (100%) 26.30 (16.18-36.42) 42 (3–81) 11 (9–12) Not detected 
TOTAL 509 453 (89%) 16 (3%) 40 (8%) 81.22 (0.02–99.63) 12,227 (1–46,996) 100 (3–100) 22 (10–43) 
Total 
excl. Run 
30 & 31 
413 381 (92%) 16 (4%) 16 (4%) 84.45 (0.02–99.63) 14,341 (1–46,996) 100 (13–100) 22 (10–40) 
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Table 2. Turn-around times and costs associated with norovirus genotyping by PCR and 488 
Sanger sequencing compared to SureSelect target enrichment full genome sequencing.  489 
Genotyping 
method 
Hands on time Total turn-
around time 
Reagent costs 
per sample 
PCR and Sanger 
sequencing* 
 
7 hrs. 3 days £32 
Full genome 
sequencing by 
SureSelect 
target 
enrichment 
11 hrs. 30 mins 6 days £86–£93**  
* PCR amplification of three sites of interest for norovirus genotyping; RNA-dependent RNA 490 
polymerase (RdRp), capsid shell domain and capsid P2 domain, including one round of 491 
nested PCR, assuming RdRp and capsid shell domain targets are amplified and sequenced 492 
simultaneously 493 
** Cost based on batches of 96 or 48 samples and sequencing on an Illumina MiSeq. 494 
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Figure legends 495 
Figure 1. Schematic of norovirus full gnome assembly pipeline 496 
 497 
Figure 2. Number of samples sequenced according to norovirus genotype, classified by 498 
sequencing outcome. Pass, >90% genome coverage and >100-fold read depth; Sub-optimal, 499 
>90% genome coverage or >100-fold read depth; Fail, , <90% genome coverage and <100-500 
fold read depth. Genotype refers to capsid genotype only. 501 
 502 
Figure 3. Norovirus full genome sequencing outcome metrics according to (a–c) norovirus 503 
genotype and (d–f) RT-qPCR Ct value. Red lines indicate median value 504 
 505 
Figure 4. RT-qPCR Ct value of all samples, excluding Run 30 and 31, (n = 413) sequenced by 506 
SureSelect. Pass, >90% genome coverage and >100-fold read depth; Sub-optimal, >90% 507 
genome coverage or >100-fold read depth; Fail, , <90% genome coverage and <100-fold 508 
read depth 509 
 510 
Figure 5. Observed and predicted % genome coverage values with 95% prediction intervals, 511 
excluding outliers identified in Figure A3. Fitted linear regression model: 𝑦 = 7.432 −512 
0.059𝑥 where the dependent variable 𝑦 is the logit transformed genome coverage 513 
proportion and the independent variable 𝑥 is the PCR Ct value (n = 477).  514 
